Six agents are currently available in this class. All are unique in structure, pharmacokinetics, and pharmacologic potency. Current evidence does not show an absolute advantage of one product over another. However, there is a difference in LDL-C lowering efficacy when comparing agents on an mg per mg basis. One should note that in most cases, similar reductions in LDL-C between agents are obtainable when dosing is altered. (see Appendix A) Table 1 below lists available statins, strengths, dosage regimens, and respective lipid lowering ability.
General Information
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• Compliance with a prescribed diet should be followed in addition to statin therapy.
• Drug interactions occur when statins are taken with a number of other drugs including anticoagulants, bile acid resins, fibrates, immunosuppressive agents, niacin, azole antifungals, some HIV drugs and macrolide antibiotics.
• Patients should be advised to report any muscle weakness, discomfort, or brown urine immediately.
Monitoring 6
• Follow-up visits every 6-8 weeks until treatment goal(s) are reached. Once goals are achieved, follow-up intervals may be reduced to every 4-6 months.
• Once treatment goal(s) are reached, lipoprotein profiles should be assessed preferably at each clinic visit, but at least annually.
• CK levels should be obtained initially and when muscle soreness, tenderness, or pain presents. Muscle symptoms should be evaluated at each visit.
• Evaluate liver function (ALT/AST) initially, approximately 12 weeks after starting, then annually or more frequently if indicated.
Safety 7
All agents are well tolerated by most persons.
• Elevated hepatic transaminases are seen in 0.5% to 2% of cases and are dose dependent. It has not been determined whether this elevation correlates with true hepatotoxicity. Progression to liver failure is rare. Reversal of liver enzyme elevation is noted with a reduction in dose, and the increase is generally not seen to recur with re-challenge or selection of another statin. Though cholestasis and active liver disease are listed as contraindications to statin use, no specific evidence exists to show exacerbation of liver disease.
• Statins' ability to produce myopathy is well established, especially when used in combination with other antihyperlipidemia medications. Severe myositis, which involves muscle aches, soreness or weakness, and elevated creatine kinase levels (> 10 times normal), is rare in those prescribed statin monotherapy. In this case, drug therapy should be discontinued to prevent progression to rhabdomyolysis, myoglobinuria, or acute renal necrosis.
• Statins are contraindicated in pregnancy and lactation. o The LIPID study showed a 24% reduction in death from CHD, 22% reduction in overall mortality, and a significantly lower number of cardiovascular events in those patients given pravastatin 40 mg daily. 11 Positive results associated with primary prevention were confirmed for pravastatin in the WOSCOPS trial. . 17 o Dosing of rosuvastatin should be started at 5 mg once daily and not exceed 10 mg once daily in patients with severe renal impairment (CLcr < 30mL/min/1.73m 2 ) not on hemodialysis. 17 o Coadministration of an antacid (aluminum and magnesium hydroxide combination) with rosuvastatin resulted in a decrease in plasma concentration of rosuvastatin by 54%. However, when the antacid is given 2 hours after rosuvastatin, there are no clinically significant changes on plasma concentrations of rosuvastatin. o If rosuvastatin is used in combination with gemfibrozil, the dose of rosuvastatin should be limited to 10 mg once daily. 17 o ~ 10% of rosuvastatin is metabolized by the P450 2C9 enzyme system. 17 
DUReport
• Precautions o Coadministration of rosuvastatin to patients on stable warfarin therapy resulted in clinically significant rises in INR (>4, baseline 2-3). When prescribing rosuvastatin and warfarin together, determine baseline INR prior to starting rosuvastatin, and monitor frequently to ensure that no significant alterations of INR occur. 17 o Consider dosing modification when prescribing rosuvastatin for patients of Japanese and Chinese descent, due to a 2-fold elevation in median exposure.
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• Cardiac Benefits o Lipid and apolipoprotein ratios have been shown to be strongly associated with CAD risk in previous studies. Pooled-data analysis showed that 12 weeks of rosuvastatin 10 mg resulted in clinically important reductions in lipid ratios that were significantly greater than those resulting from the treatment with the usual starting dose of atorvastatin, simvastatin, or pravastatin. o The Heart Protection Study demonstrated a 25% reduction in the first event rate for major coronary events, stroke, and revascularizations in patients given simvastatin 40 mg daily. 13 A significant reduction in all case mortality for primary prevention was shown with simvastatin in the 4S trial. • Reduction in LDL-C of 25-42% with doses ranging from 10-60 mg, increased HDL-C 3-8%, and decreased triglycerides 18-33% • Allows lovastatin to be taken on an empty stomach therefore, increasing absorption.
ADVICOR
® (combination product of Niacin extended-release and lovastatin) 15 • Approved by the FDA in December of 2001
• Reduced mean LDL-C 45%, increased mean HDL-C 41%, and decreased mean triglyceride levels by 42% • Decreased risk of flushing due to extended-release formulation of niacin.
• Increased risk of myopathy vs. lovastatin alone.
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PRAVIGARD PAC
™ [Combination of pravastatin (Pravachol®) and buffered aspirin] • Indicated in patients for whom treatment with both pravastatin and buffered aspirin is appropriate • Indicated to reduce the occurrence of cardiovascular events, including death, myocardial infarction or stroke, in patients who have clinical evidence of cardiovascular and/or cerebrovascular disease.
PITAVASTATIN ™ 16
• Pitavastatin is not FDA approved, but is in Phase III trials • Pitavastatin has similar efficacy data to date as rosuvastatin.
• Pitavastatin is not metabolized by the p450 3A4 enzyme system, therefore is expected to show efficacy somewhat similar to rosuvastatin with fewer drug interactions. NOTE: From this table you can see that there is a difference in the effectiveness to lower LDL-C when comparing agents on a mg per mg basis. However, note that you can obtain similar reductions in LDL-C between agents when dosing is altered to produce similar effects. 
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